FIGURES

Figure 1A.



Figure 1B.


110
100
90
80
70
60
50
40
30
20
cell number
(% of
control)
Des (1-3)IGF-I
KGF
Testosterone
10^{-18}
10^{-16}
10^{-14}
10^{-12}
10^{-10}
10^{-8}
Cmpd A (M)

Figure 2A.


BPH Cell No. (% of control)
140
120
100
80
60
40
20
0
100
50
0
control
T + Cmpd A
T + F
T + Cyp
Cmpd A
F
Cyp
*
*°
*°
*°
*

Figure 2B.


BPH cell number (% of control)
160
140
120
100
80
60
40
20
0
10
5
0
*
*
o
o
o
control
DHT + Cmpd A
DHT + F
DHT + Cyp

Figure 3A.


100
80
60
40
20
0
% of activity
EC50 = 2.02 ± 1.3 nM
n= 4
Cmpd A
DHT
10-12
10-11
10-10
10-9
10-8
10-7
10-6

Figure 3B.


100
80
60
40
20
% of activity
n= 4
Cmpd A
Bicalutamide
IC50= 194 ± 80 nM
10-9
10-8
10-7
10-6
10-5
+ DHT (3 nM)

Figure 4A.


castrated rats
+T 30 mg/Kg
Ventral Prostate Weight (% of control)
180
160
140
120
100
80
60
40
20
0
control
10
30
100
300
1
40
Cmpd A (µg/Kg)
Finasteride (mg/Kg)

Figure 4B.


100
80
60
40
20
0
Ventral prostate weight (% of control)
control
10
30
100
300
10
40
Cmpd A (µg/Kg)
Finasteride (mg/Kg)

Figure 5.


A
1 2 3 4 5 6
clusterin -
GAPDH -
- 28 S
- 18 S
B
1 2 3 4
clusterin -
GAPDH -
- 28 S
- 18 S

Figure 6.



Figure 7.



Figure 8.



Percent reduction	15	6.4	21

Figure 9.



Percent reduction	44

Figure 10



Figure 11



Figure 12



Figure 13



Figure 14



Figure 15



Figure 16



Figure 17

